- Sinigrin
-
- $69.00 / 10mg
-
2025-05-30
- CAS:3952-98-5
- Min. Order:
- Purity: 98.92%
- Supply Ability: 10g
- Sinigrin
-
- $0.00 / 20mg
-
2023-02-24
- CAS:3952-98-5
- Min. Order: 20mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- SINIGRIN
-
- $1.00 / 1kg
-
2019-07-06
- CAS:3952-98-5
- Min. Order: 1kg
- Purity: 95%-99%
- Supply Ability: 10kg
|
| | SINIGRIN Basic information |
| | SINIGRIN Chemical Properties |
| Melting point | 128 (dec.)(lit.) | | storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere | | solubility | DMSO (Slightly), Methanol (Slightly), Water (Slightly) | | form | Solid | | color | White | | biological source | plant (Brassica nigra) | | optical activity | [α]20/D 17±1°, c = 1% in H2O | | Water Solubility | almost transparency | | Merck | 14,8545 | | Stability: | Hygroscopic | | LogP | 1.049 (est) | | CAS DataBase Reference | 3952-98-5 |
| Safety Statements | 24/25 | | WGK Germany | 3 | | RTECS | LZ5778000 | | HS Code | 29389090 |
| | SINIGRIN Usage And Synthesis |
| Uses | Sinigrine, is a glucosinolate which is found naturally in Cruciferae including the genus Brassica. When enzymatically hydrolysed, Sinigrine yields isothiocyanates and give a pungent taste. Both Sinigrine, and isothiocyanates, have been shown to have anticancer activity as well as antifungal and antibacterial properties. | | Uses | Sinigrin, a glucosinolate, is used as a systrate to identify, differentiate and characterize myrosinase(s)/thioglucoside glucohydrolase(s)/thioglucosidase(s). Sinigrin is used as a reference material in procedures for the isolation and identification of glucosinolates. | | Definition | ChEBI: An alkenylglucosinolate that is the conjugate base of sinigrin. | | Biochem/physiol Actions | A β-D-thioglucopyranoside occurring in black mustard seeds and horseradish root. Substrate for thioglucosidase. | | in vivo | Sinigrin (15-30 mg/kg; Oral administration; for 12 days) exerts protective and therapeutic effects on DSS?induced colitis, by enhancing the anti-oxidant enzymes and suppressing the intestinal inflammatory cascade of markers by regulating the MAPK pathway[2]. | Animal Model: | A dextran sulfate sodium (DSS)-induced mouse model[2] | | Dosage: | 15 mg/kg or 30 mg/kg | | Administration: | Oral administration; for 12 days | | Result: | Significantly mitigated the DSS-induced body weight loss, attenuated the colon length shrinkage, and improved the disease index score. Successfully abrogated the DSS-induced IL-17 levels and improved the colonic barrier in colon tissues. |
|
| | SINIGRIN Preparation Products And Raw materials |
|